Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Coherus Oncology (CHRS) Long-Term Debt Issuances (2016 - 2024)

Coherus Oncology's Long-Term Debt Issuances history spans 6 years, with the latest figure at -$141000.0 for Q3 2024.

  • For Q3 2024, Long-Term Debt Issuances changed N/A year-over-year to -$141000.0; the TTM value through Dec 2024 reached $49.3 million, changed N/A, while the annual FY2024 figure was $37.0 million, N/A changed from the prior year.
  • Long-Term Debt Issuances for Q3 2024 was -$141000.0 at Coherus Oncology, down from $49.5 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $222.2 million in Q1 2021 and bottomed at -$674000.0 in Q3 2020.
  • The 4-year median for Long-Term Debt Issuances is $25.1 million (2020), against an average of $77.1 million.
  • The largest YoY upside for Long-Term Debt Issuances was 240.54% in 2020 against a maximum downside of 535.85% in 2020.
  • A 4-year view of Long-Term Debt Issuances shows it stood at -$674000.0 in 2020, then surged by 33067.36% to $222.2 million in 2021, then tumbled by 77.73% to $49.5 million in 2022, then tumbled by 100.28% to -$141000.0 in 2024.
  • Per Business Quant, the three most recent readings for CHRS's Long-Term Debt Issuances are -$141000.0 (Q3 2024), $49.5 million (Q3 2022), and $191.2 million (Q1 2022).